bluebird bio, Inc. (NASDAQ:BLUE) posted its earnings results on Wednesday. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05), Briefing.com reports. The business had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s revenue for the quarter was up 397.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.07) EPS.

In related news, insider Nick Leschly sold 7,050 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $145.14, for a total value of $1,023,237.00. Following the completion of the transaction, the insider now directly owns 259,059 shares of the company’s stock, valued at $37,599,823.26. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Daniel Lynch sold 500 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the transaction, the director now directly owns 3,300 shares of the company’s stock, valued at $396,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 150,002 shares of company stock valued at $18,840,335. Insiders own 3.90% of the company’s stock.

BLUE has been the subject of several recent research reports. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald reiterated a “sell” rating and issued a $39.00 target price on shares of bluebird bio in a research note on Thursday, September 28th. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective for the company in a research note on Monday, October 16th. BMO Capital Markets boosted their price objective on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research note on Monday. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $129.25.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/bluebird-bio-inc-blue-releases-quarterly-earnings-results-misses-estimates-by-0-05-eps.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.